TARRYTOWN, N.Y. and PARIS, April 30, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of…

View more at https://www.prnewswire.com/news-releases/fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-300638681.html